



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



JQAD1

Item No. 39566

CAS Registry No.: 2417097-18-6
Formal Name: 12-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisindolin-5-yl)amino)-((R)-3'-((4-fluorobenzyl)((S)-1,1,1-trifluoropropan-2-yl)amino)-2-oxoethyl)-2',4'-dioxo-2,3-dihydrospiro[indene-1,5'-oxazolidin]-5-yl)dodecanamide

Synonym: (R,S)-JQAD1

MF: C₄₈H₅₂F₄N₆O₉


FW: 933.0

Purity: ≥98%

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

JQAD1 is supplied as a solid. A stock solution may be made by dissolving the JQAD1 in the solvent of choice, which should be purged with an inert gas. JQAD1 is soluble in DMSO.

Description

JQAD1 is a proteolysis-targeting chimera (PROTAC) composed of the p300 and CREB-binding protein (CBP) inhibitor A-485 (Item No. 24119) conjugated to a cereblon (CRBN) ligand.¹ It selectively induces the degradation of p300 over CBP in Kelly MYCN-amplified neuroblastoma cells when used at a concentration of 10 μM for 24 hours. JQAD1 (0.5 μM) decreases histone 3 lysine 27 (H3K27) acetylation and induces apoptosis in Kelly cells. *In vivo*, JQAD1 (40 mg/kg) decreases tumor volume, increases survival, and reduces tumoral p300 but not CBP levels in a Kelly neuroblastoma mouse xenograft model.

Reference

1. Durbin, A.D., Wang, T., Wimalasena, V.K., *et al.* EP300 selectively controls the enhancer landscape of MYCN-amplified neuroblastoma. *Cancer Discov.* **12**(3), 730-751 (2022).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/17/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM